CAMBRIDGE, Massachusetts, August 30, 2026, 16:12 (ET)
- Shares of Moderna dropped 3.35% on Friday, with trading volume reaching 178% of its average level.
- The company is still over 130% higher following its melanoma vaccine results.
- Analysts project cancer-vaccine revenues will top $1 billion by 2030 and reach $3 billion by 2035.
- Revenue in the second quarter reached $145 million, while the net loss totaled $782 million.
Moderna Inc. (NASDAQ: MRNA) dropped 3.35% to $137.99 on Friday. Trading volume totaled 25.82 million shares, representing 178% of its 65-day average, according to MarketWatch.
The recent decline had minimal impact on the cancer-vaccine sector’s revaluation. Moderna’s market capitalization stays close to $55.1 billion, up over 130% following the trial outcome.
The valuation is now driven by commercial performance rather than scientific feasibility. Analysts on Wall Street project sales of intismeran autogene to exceed $1 billion by 2030 and reach $3 billion by 2035.
| Measure | Latest figure | Investor read |
|---|---|---|
| Friday close | $137.99; fell 3.35% | Heavy selling prompted by profit-taking |
| Market capitalization | $55.09 billion | Valued at 18.4× forecast 2035 cancer-vaccine revenue |
| Q2 revenue | $145 million | Approximately 2% higher than previous year |
| Q2 net loss | $782 million | Equals 5.4× Q2 revenue |
| June cash and investments | $6.9 billion | $600 million lower than the prior period |
| Projected year-end cash | $4.7 billion–$5.2 billion | Does not include potential new credit lines |
The experimental therapy prevented melanoma from recurring or advancing in a late-stage trial involving over 1,000 participants. U.S. authorization may be possible next year Reuters.
Moderna and Merck & Co. (NYSE: MRK) split both the expenses and revenue for the program. Merck made an initial payment of $200 million in 2016, followed by an additional $250 million in 2022.
The platform’s constraints were also highlighted on Friday. BioNTech SE (NASDAQ: BNTX) halted a colorectal cancer vaccine trial due to a survival imbalance, causing its shares to fall 8.37%.
Analysts described this outcome as a cautionary sign for “cold” tumors, which are unresponsive to immunotherapy. Melanoma features a higher number of mutations, providing additional targets for Moderna’s personalized vaccine Reuters.
The financial gap continues to be costly. Moderna posted a loss of $782 million on $145 million in second-quarter revenue and used $600 million in cash and investments.
The company disbursed a $950 million settlement in July related to litigation. Management forecasts year-end cash and investments in the range of $4.7 billion to $5.2 billion Moderna.
Analyst revisions highlight the uncertainty. Argus assigned a Buy rating with a $180 price target. JPMorgan maintained an Underweight stance and a $77 target. UBS and Jefferies raised their targets to $150, but both maintained Neutral or Hold ratings.
Risks: Complete trial results may challenge current market expectations. Producing individualized doses, obtaining reimbursement, and expanding beyond melanoma could face delays.
The upcoming valuation milestone involves comprehensive melanoma data set to be released at a leading cancer conference in Madrid this October. Investors are set to scrutinise both the magnitude and reliability of the clinical benefit.
Related articles: NASDAQ:MRNA
